Polyamines Put Dangerous Iron Away for Cells: Study Uncovers a Metabolic Buffer Against Ferroptosis

Iron is indispensable to cells, yet difficult to control. It supports energy metabolism and the function of numerous enzymes, but when free in a reactive form, it can catalyze oxidative reactions that damage lipids, proteins, and nucleic acids. A team at the Whitehead Institute now proposes that cells rely on a group of small molecules called “polyamines” to temporarily constrain this reactive iron in a safer state, forming a previously unrecognized layer of metabolic buffering.

The study began with a genome-wide CRISPR screen. The team inhibited polyamine synthesis in human K562 cells and then examined, one by one, how approximately 20,000 protein-coding genes affected cell survival. They found that when polyamines were deficient, cells became highly dependent on GPX4. This enzyme suppresses lipid peroxidation and is also an important defense against “ferroptosis”; when polyamine depletion and loss of GPX4 function occurred simultaneously, the cells exhibited a synthetic lethal effect.

The key was not that the cells absorbed more iron. Experiments showed that after polyamine levels fell, the cells’ total iron content did not increase significantly. What changed was the distribution of iron within the cells: the redox-active “labile iron pool” expanded, and ferritin levels also rose. Supplementing polyamines or adding an iron chelator reduced the associated lipid oxidation and cell death, supporting a model in which polyamines directly or indirectly sequester reactive iron.

To observe this process, the researchers used the cells’ native iron-responsive regulatory system to design a genetically encoded fluorescent sensor and paired it with a polyamine sensor. Single-cell analysis showed that the lower the polyamine content, the higher the reactive iron signal generally was. The publicly available CRISPR data came from K562 cells; separate lipidomics data compared treatment with the polyamine inhibitor sardomozide, the iron chelator deferoxamine, and a combination of the two, providing another layer of evidence for the link between iron and lipid oxidation.

This mechanism also suggests a cancer treatment concept. Because some anticancer strategies are attempting to reduce polyamines in tumor cells, additionally inhibiting GPX4 could theoretically push cancer cells toward ferroptosis. However, the current evidence comes mainly from cultured cells and organoids, and it has not yet been shown that this combination can selectively kill tumors in animals or patients. Whether normal tissues would also be harmed by increased reactive iron is an even more critical safety question that must be answered before treatment.

The Whitehead Institute said the findings have been published in *Cell*; the publicly verifiable PubMed record, however, still corresponds to the preprint version released in 2025. The study also proposed that polyamine deficiency may help explain some forms of early-onset Parkinson’s disease accompanied by iron accumulation, but this is currently only a mechanistic link, not evidence of therapeutic efficacy in patients. Two authors are listed as inventors on a related pending patent, making subsequent validation of the sensing tools and therapeutic combination, as well as disclosure of interests, particularly important.